Oliceridine Versus Sufentanil Analgesia for Postoperative Patients With Obstructive Sleep Apnea

Sponsor
Peking University First Hospital
Study ID
NCT07753785
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Obstructive Sleep Apnea
  • Oliceridine
  • Postoperative Analgesia
  • Respiratory Depression
  • Sufentanil

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Oliceridine — DRUG
    Oliceridine will be administered via patient-controlled intravenous analgesia.
  • Sufentanil — DRUG
    Sufentanil will be administered via patient-controlled intravenous analgesia.

Study Details

Opioids are frequently used for postoperative analgesia but may induce side effects. Opioid-induced respiratory depression is the most dangerous side effect of opioids. Patients with obstructive sleep apnea (OSA) are at higher risk for opioid-induced respiratory depression. Oliceridine is a novel biased μ-opioid receptor agonist that selectively engages the G-protein pathway while reducing β-arrestin recruitment and thus may lower the risk of respiratory depression. The goal of this observational study is to compare the effects of oliceridine versus sufentanil analgesia on the incidence of postoperative respiratory depression in patients with known or suspected OSA in the postoperative period following elective surgery.

Key Dates

First listed
Aug 10, 2026
Start date
Sep 30, 2026
Status verified
Aug 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2029

Study Design

Enrollment
851 participants (estimated)

Arms

  • Arm: Oliceridine cohort
    Patients will receive oliceridine via patient-controlled intravenous analgesia.
  • Arm: Sufentanil cohort
    Patients will receive sufentanil via patient-controlled intravenous analgesia.

Primary Outcome Measure

Incidence of respiratory depression within 24 hours after surgery [ Time Frame: Within 24 hours after surgery ]

Central Contacts

Related Studies